含着jing液去上课h男男,糟蹋稚嫩的身体发泄h,精品无人乱码一区二区三区,和尚吮她的花蒂和奶水视频

Stock(600222)Hot line:010-61006450

News

Understand the latest news of Leadingpharm

Leadingpharm and China Biology Signed an Agreement of Phase-I Clinical Research on a New Drug for Type 2 Diabetes

Release time:2021-07-28

Recently, Leadingpharm signed a cooperation agreement with China Biology on the phase I clinical research project of "insulin secreting peptide fusion protein injection". The project is developed by Lanzhou Institute of biological products of China Biology. Leadingpharm will be responsible for providing phase I clinical research services. The conclusion of this cooperation marks that Leadingpharm has officially joined the ranks of clinical CRO suppliers of China Biology and started the journey of strategic cooperation.
 

China Biology

China Biology was found in 1919 and is directly under the leadership of the National Health Commission. Now it is an important member enterprise of China Pharmaceutical Group, which is an enterprise of the world's top 500. It is a comprehensive biopharmaceutical enterprise in China with a long history, complete products and large scale, integrating scientific research, production, sales and postgraduate training. It has 12 secondary subsidiaries including Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products and Wuhan Institute of Biological Products and 76 subsidiaries below secondary level, with 12551 employees. The company has a rich product line, covering six biological products fields: human vaccine, blood products, medical beauty, animal health care, antibody drugs and medical diagnosis. The annual output of 50 kinds of vaccines for human use can exceed 700 million doses, ranking sixth in the world, providing more than 80% of the vaccines for national immunization planning. Listed companies with an annual plasma collection volume of more than 1500 tons are producing 11 kinds of blood products. As the only botulinum toxin manufacturer certified and approved by the government in China, products are highly recognized by the market, providing the society with all-round and high-quality services for animal vaccines and related animal biological products. It has a complete antibody drug industry chain and a large molecular diagnosis industry chain with distinctive characteristics.
 

Leadingpharm

Leadingpharm (stock code: 600222) was established in 2005. It is a high-tech enterprise providing pharmacy pre-clinical research, clinical CRO and CDMO services to the whole world. It has been rated as "China’s Top 10 Pharmaceutical R&D Enterprises "for many years (ranked first in 2019). The company has nearly 1,000 R&D personnel, 80% of whom have a master's degree or above, all from well-known universities at home and abroad, specializing in medicinal chemistry, drug analysis and pharmaceutical preparations. The core R&D personnel have been engaged in the professional research work for many years, have rich experience in the development and production of new drugs, and have a thorough interpretation of registration regulations and guidelines. At present, more than 500 clinical studies have been completed, 50 to 100 BE studies and 10 to 20 clinical studies of Class I new drugs can be completed every year. Based on the rich experience in pharmaceutical R & D and clinical CRO of Leadingpharm and the CXO Integrated Service System Platform, it can meet the different needs of enterprises and provide good help for the transformation of innovative drugs.Based on Leadingpharm’s rich experience in pharmaceutical R & D and Clinical CRO and its CXO integrated service system platform, it can meet the different needs of enterprises and provide good help for the transformation of innovative drugs.
 

It is reported that "Insulin Secreting Peptide Fusion Protein Injection" is a GLP-1 receptor agonist. In vivo, it can promote insulin in islet B cells in a glucose concentration dependent manner by binding with GLP-1 receptor and activating the receptor, and reduce the secretion of glucagon in cells, so as to reduce blood glucose and have the effect of safe and effective control of blood samples. Compared with insulin, sulfonylurea and other routine drugs, the insulin secreting peptide fusion protein injection is expected to achieve good blood glucose control goal once every 10~15 days, and is more conducive to the treatment of patients with type 2 diabetes.

 

With the signing of the cooperation agreement between the two sides, the project will officially enter the phase I clinical research stage. The two sides will set up a project team to tackle tough problems and speed up the quality and efficiency of the project, and strive to promote early release of the fusion protein injection of insulin secreting peptide, which will bring more convenient treatment options for diabetics. Meanwhile, the two sides will continue to explore more levels of cooperation opportunities, access China's biological innovative drug platform with the CXO Whole Industry Chain Service System of Leadingpharm, inject new momentum into the R & D and transformation of innovative drugs, and jointly promote the development of China's pharmaceutical industry.
 

-END-

轉(zhuǎn)載聲明:未經(jīng)本網(wǎng)或本網(wǎng)權(quán)利人授權(quán),不得轉(zhuǎn)載、摘編或利用其他方式使用上述作品。已經(jīng)本網(wǎng)或本網(wǎng)權(quán)利人授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來源:新領(lǐng)先醫(yī)藥科技”。

Recommend

少妇真实被内射视频三四区| 国产真实乱了露脸在线观看| 粗大好烫轻点太深好硬好涨视频| 免费在线观看成人电影| 我把五十老女人弄高潮了| 日本三级片在线观看| 国产做a爰片毛片a片美国| 熟睡人妻被讨厌的公侵犯| 一二三四社区在线高清观看| jealousvue成熟分类| 精品一品国产午夜福利视频| 精品少妇高潮蜜臀涩涩av| 特级bbbbbbbbb视频| 被主人惩罚在惩戒室sm| 秘书被老板cao到合不拢腿| 亚洲香蕉成人av网站在线观看| 精品亚洲一区二区三区四区五区| 学长边洗澡边把我处破了小说| 亚洲 日韩 欧美 综合 热| 男人放进女人阳道视频观看| 日本A片把舌头伸进粉嫩| 我的邻居是bj无删减漫画免费看| 妺妺窝人体色www在线小说| 再深点灬舒服灬受不了了视频| 免费真人视频网站直播下载| 全彩调教本子h里番全彩无码| 国产农村妇女毛片精品久久| 曰本女人与公拘交酡| A片欧美激情肉欲高潮| 欧美又大粗又爽又黄大片视频| 免费真人视频网站直播下载| 胖老太bbwbbwbbwbbw| 天堂网在线最新版www中文网| 精产国品一二三产品区别图片| 全免费a级毛片免费看| 国产人与zoxxxx另类| 黄色电影网站| 苍井空办公室33分钟| 色喜国模私密浓毛私拍人体图片| 人鲁交yazhonghucxx| 久久99精品久久久久久无毒不卡|